Next Article in Journal
Can We Explain Thousands of Molecularly Identified Mouse Neuronal Types? From Knowing to Understanding
Previous Article in Journal
2α-Substituted Vitamin D Derivatives Effectively Enhance the Osteoblast Differentiation of Dedifferentiated Fat Cells
Previous Article in Special Issue
Imipramine Treatment Alters Sphingomyelin, Cholesterol, and Glycerophospholipid Metabolism in Isolated Macrophage Lysosomes
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Biomolecules
Volume 14
Issue 6
10.3390/biom14060707
biomolecules-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Rapid Movement of Palmitoleic Acid from Phosphatidylcholine to Phosphatidylinositol in Activated Human Monocytes

by
Miguel A. Bermúdez
1,2,†,
Alvaro Garrido
1,2,
Laura Pereira
1,2,
Teresa Garrido
1,2,
María A. Balboa
2,3,* and
Jesús Balsinde
1,2,*
1
Bioactive Lipids and Lipidomics Core, IBGM, CSIC-UVA, 47003 Valladolid, Spain
2
Centro de Investigación Biomédica en Red de Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM), Instituto de Salud Carlos III, 28029 Madrid, Spain
3
Lipid Metabolism and Inflammation Group, IBGM, CSIC-UVA, 47003 Valladolid, Spain
*
Authors to whom correspondence should be addressed.
†
Current address: Facultad de Ciencias y Artes, Universidad Católica de Avila (UCAV), 05005 Avila, Spain.
Biomolecules 2024, 14(6), 707; https://doi.org/10.3390/biom14060707
Submission received: 20 May 2024 / Revised: 10 June 2024 / Accepted: 13 June 2024 / Published: 15 June 2024
(This article belongs to the Collection Feature Papers in Biomacromolecules: Lipids)
Browse Figures
Versions Notes

Abstract

:
This work describes a novel route for phospholipid fatty acid remodeling involving the monounsaturated fatty acid palmitoleic acid. When administered to human monocytes, palmitoleic acid rapidly incorporates into membrane phospholipids, notably into phosphatidylcholine (PC). In resting cells, palmitoleic acid remains within the phospholipid pools where it was initially incorporated, showing no further movement. However, stimulation of the human monocytes with either receptor-directed (opsonized zymosan) or soluble (calcium ionophore A23187) agonists results in the rapid transfer of palmitoleic acid moieties from PC to phosphatidylinositol (PI). This is due to the activation of a coenzyme A-dependent remodeling route involving two different phospholipase A2 enzymes that act on different substrates to generate free palmitoleic acid and lysoPI acceptors. The stimulated enrichment of specific PI molecular species with palmitoleic acid unveils a hitherto-unrecognized pathway for lipid turnover in human monocytes which may play a role in regulating lipid signaling during innate immune activation.

1. Introduction

The escalating prevalence of diabetes and related metabolic conditions constitutes a pressing concern. Avoiding excess weight appears to be a predominant strategy [1,2,3]. Obesity-induced diabetes often leads to cardiovascular complications, including heart attack and stroke, which involve, to a significant extent, the altered functioning of monocytes and macrophages. Obesity triggers systemic, low-grade inflammation characterized by the elevated levels of immune cells, predominantly macrophages, in metabolic tissues like the skeletal muscle, adipose, and liver. Thus, the accumulation of pro-inflammatory monocyte-derived macrophages in tissues stands as a hallmark of metabolic inflammation in obesity [4,5,6,7,8,9,10,11].
Given their pivotal roles in both physiology and pathophysiology, monounsaturated fatty acids are emerging as significant health indicators. Oleic acid (cis-9-octadecenoic acid, 18:1n–9), the predominant monounsaturated fatty acid in human diets, is particularly abundant in olive oil, constituting nearly 80% of its total fatty acid content [12,13]. The Mediterranean diet, renowned for its health-promoting effects and cardio-protective benefits against diseases like cardiovascular diseases, diabetes, and obesity, features a high consumption of olive oil [14,15].
Recent research has brought another monounsaturated fatty acid, palmitoleic acid (cis-9-hexadecenoic acid, 16:1n–7, POA), into the limelight of inflammatory lipid research due to its protective effects against hepatic steatosis and its role in enhancing insulin signaling in murine models of metabolic disorders [16,17]. Elevated levels of POA in humans have been shown to correlate with improved insulin sensitivity, a favorable lipid profile, and the reduced incidence of type-2 diabetes and cardiovascular diseases such as myocardial infarction [18]. Additionally, POA reduces inflammation by decreasing circulating pro-inflammatory cytokines and inflammatory markers in various tissues [19,20,21,22,23,24]. This anti-inflammatory activity of POA is quite significant when assessed in cells of the innate immune system, where it is generally comparable to that of omega-3 fatty acids [25,26].
POA can be obtained from dietary sources such as macadamia nuts, dairy, and certain fish. It can also be synthesized via the desaturation of palmitic acid (hexadecanoic acid, 16:0), primarily in adipose tissue and the liver, by stearoyl-CoA desaturase-1, a Δ9 desaturase enzyme [27,28]. Likewise, the incorporation and distribution of POA into the major classes of cellular lipids have recently been characterized in macrophages [26,29]. Results from these studies have shown that in resting phagocytic cells, which generally exhibit low levels of neutral lipids, POA tends to accumulate in membrane phospholipids, particularly phosphatidylcholine (PC) [26,29]. Conversely, in cells with abundant lipid droplets, significant POA localization occurs in these organelles, suggesting a pivotal role of the fatty acid in their metabolism [25,30]. In this study, we have examined the turnover of POA-containing phospholipids in stimulated human monocytes. Our previous work using murine peritoneal macrophages suggested that low POA levels can be mobilized from membrane phospholipids to form POA-containing branched fatty acid esters of hydroxy fatty acids [29], a family of compounds known for their potent anti-inflammatory activity in vivo [31,32]. Our study expands on these findings by utilizing distinct strategies to label the various phospholipid pools. The data suggest that POA is rapidly shuttled between specific phospholipid pools during monocyte activation. This novel lipid remodeling pathway may be instrumental in the execution of specific responses by the activated monocytes.

2. Materials and Methods

2.1. Reagents

Organic solvents (Optima® LC-MS grade) were from Fisher Scientific (Madrid, Spain). Lipid standards were from Cayman (Ann Arbor, MI, USA) or Avanti (Alabaster, AL, USA). Silicagel G thin-layer chromatography plates were from Macherey-Nagel (Düren, Germany). Additionally, [9,10-3H]POA (sp. act. 30–60 Ci/mmol) was from American Radiolabeled Chemicals (St. Louis, MO, USA). The group IVA phospholipase A2 (cytosolic phospholipase A2α; cPLA2α) inhibitor pyrrophenone [33] and the CoA-independent transacylase inhibitor SKF98625 [34] were synthesized and provided by Dr. Alfonso Pérez (Department of Organic Chemistry, University of Valladolid). The group VIA phospholipase A2 (calcium-independent phospholipase A2β; iPLA2β) inhibitors FKGK18 and BEL, and the secreted phospholipase A2 (sPLA2) inhibitor LY311727, were from Cayman. All other reagents were purchased from Sigma-Aldrich (Madrid, Spain).

2.2. Cell Isolation and Culture

Human peripheral blood monocytes were obtained from buffy coats of healthy anonymous volunteer donors provided by the Centro de Hemoterapia y Hemodonación de Castilla y León (Valladolid, Spain). Written informed consent was obtained from each donor. The buffy coats were diluted 1:1 with phosphate-buffered saline (PBS), and the mononuclear cells were collected by centrifugation at 750× g for 30 min over a Ficoll-Paque cushion. The mononuclear cell ring was recovered, washed three times with PBS, and allowed to adhere on sterile dishes for 2 h at 37 °C. Nonadherent cells were removed by washing extensively with PBS. The adhered monocytes were placed in RPMI 1640 medium (Molecular Probes-Invitrogen, Carlsbad, CA, USA) supplemented with 40 µg/mL gentamicin, and used the following day [35,36]. All experiments were conducted in serum-free media. For the preparation of zymosan, the particles were suspended in PBS, boiled for 60 min, and washed three times. The final pellet was resuspended in PBS at 20 mg/mL, and stored frozen. Zymosan aliquots were diluted in serum-free medium and sonicated before addition to the cells [37]. To obtain opsonized zymosan, the particles were treated with heat-inactivated human serum (3 mg zymosan per mL serum) for 20 min at 37 °C. No phospholipase A2 activity was detected in the zymosan batches used in this study, as assessed by in vitro assay under different conditions [38,39,40]. Cell protein content was quantified according to Bradford [41], using a commercial kit (BioRad Protein Assay, Bio-Rad, Hercules, CA, USA).

2.3. Measurement of POA Incorporation into Phospholipids and Phospholipid Remodeling

The cells were exposed to [9,10-3H]POA (0.25 µCi/mL) for different periods of time. Total lipids in the cell monolayers were extracted according to Bligh and Dyer [42]. The lipids were separated by thin-layer chromatography using n-hexane/diethyl ether/acetic acid (70:30:1, v/v/v) as the mobile phase [43]. The phospholipid classes were separated by thin-layer chromatography, using plates impregnated with boric acid [44], and the process was run twice. The mobile phase consisted of chloroform/methanol/28% (w/w) ammonium hydroxide (60:37.5:4, v/v/v) [45,46]. The different bands were scraped from the plates and their radioactive content was determined by scintillation counting using a LS 6500 counter (Beckman Coulter, Brea, CA, USA). For the analysis of phospholipid fatty acid remodeling, the cells were pulse-labeled with 1 nM [3H]POA (0.25 μCi/mL) for 30 min at 37 °C. The cells were then washed with medium containing 0.5 mg/mL bovine serum albumin to remove the non-incorporated label. Afterward, the cells were placed in serum-free medium and incubated at 37 °C for the indicated periods of time. After lipid extraction, the phospholipid classes were separated by thin-layer chromatography, as indicated above. The spots corresponding to each phospholipid class were cut out and assayed for radioactivity by liquid scintillation counting [47,48].

2.4. Gas Chromatography–Mass Spectrometry (GC-MS) Analyses

Cell samples (approx. 107 cells) were washed with PBS, lysed with water, and sonicated in a tip homogenizer twice for 15 s prior to total lipid extraction, according to Bligh and Dyer [42]. The following internal standard was added before lipid extraction: 10 nmol of 1,2-diheptadecanoyl-sn-glycero-3-phosphocholine. Lipid classes were separated by thin-layer chromatography, as described in the preceding paragraph. The bands corresponding to the different phospholipid classes were scraped from the plate, and fatty acid methyl esters were obtained by transmethylation with 500 µL of 0.5 M KOH in methanol for 60 min at 37 °C [49,50]. Then, 500 µL of HCL was added to neutralize, and fatty acid methyl esters were extracted twice with 500 µL of n-hexane. The analysis of fatty acid methyl esters was carried out using an Agilent 6890 N gas chromatograph coupled to an Agilent 5975 mass-selective detector operated in electron impact mode (EI, 70 eV), equipped with an Agilent DB23 column (60 m × 0.25 mm internal diameter × 0.15 μm film thickness) (Agilent Technologies, Santa Clara, CA, USA) [49,50]. Then, 1 μL of sample was injected in splitless mode. The inlet temperature was maintained at 250 °C. The oven temperature was held at 50 °C for 1 min, and then increased to 175 °C at intervals of 25 °C per min, and to 230 °C at intervals of 2.75 °C per min. The final temperature was maintained for 5 min, and the run time was 33 min. The mass spectrometry transfer line was maintained at 250 °C and the mass spectrometer quadrupole and source at 150 °C and 230 °C, respectively. Helium was used as a carrier gas at a constant pressure of 180 kPa. Data acquisition was carried out in both scan and selected ion monitoring modes. Scan mode was used for compound identification. This was accomplished by comparing with authentic standards and the National Institute of Standards and Technology Mass Spectrometry library spectra (Gaithersburg, MD, USA). Selected ion monitoring mode was used for quantitation, using 74 and 87 fragments for saturated, 83 for monounsaturated, 67 and 81 for diunsaturated and 79 and 91 for polyunsaturated fatty acid methyl esters. A 37-component mixture was used for calibration curves (Supelco Inc., Bellefonte, PA, USA), and nonadecanoic acid was used as an internal standard. Data analysis was carried out with the Agilent G1701EA MSD Productivity Chemstation software, revision E.02.00.

2.5. Liquid Chromatography/Mass Spectrometry (LC-MS) Analyses

Lipids corresponding to 50 µg of cell homogenate protein were extracted according to Bligh and Dyer [42], and the following internal standards were added: 20 pmol each of 1,2-dimyristoyl-sn-glycero-3-phosphoglycerol, 1,2-dilauroyl-sn-glycero-3-phosphoethanolamine, 1,2-dimyristoyl-sn-glycero-3-phosphoethanolamine, 1,2-diheptadecanoyl-sn-glycero-3-phosphoethanolamine, 1,2-dimyristoyl-sn-glycero-3-phosphoserine, 1,2-dimyristoyl-sn-glycero-3-phosphate, 1,2-dipentadecanoyl-sn-glycero-3-phosphocholine, 1,2-diheptadecanoyl-sn-glycero-3-phosphocholine, and 1,2-dinonadecanoyl-sn-glycero-phosphocholine. The samples were re-dissolved in hexanes/2-propanol/water (42:56:2, v/v/v) and injected into a Thermo Fisher Scientific Dionex Ultimate 3000 high-performance liquid chromatograph equipped with an Ultimate HPG-3400SD standard binary pump and an Ultimate ACC-3000 autosampler column compartment (Thermo Fisher Scientific, Waltham, MA, USA). Separation was carried out using a FORTIS HILIC (150 × 3 mm, 3 µm particle size) (Fortis Technologies, Neston, UK). The mobile phase consisted of a gradient of solvent A (hexanes/isopropanol, 30:40, by volume) and solvent B (hexanes/isopropanol/20 mM ammonium acetate in water, 30:40:7, v/v/v). The gradient started at 75% A from 0 to 5 min, then decreased from 75% A to 40% A at 15 min and from 40% A to 5% A at 20 min, then held at 5% until 40 min, and increased to 75% at 41 min. Then, the column was re-equilibrated, holding at 75% A for an additional 14 min period before the next sample injection [51]. Phospholipid species were analyzed in scheduled multiple reaction monitoring mode with negative ionization. All glycerophospholipids were detected as [M-H]– ions except choline glycerophospholipids, which were detected as [M + CH3COO]− ions. Quantification was carried out by integrating the chromatographic peaks of each species and comparing with the peak area of the internal standards that corresponded to each class. The flow rate through the column was fixed at 0.4 mL/min. The liquid chromatography system was coupled online to an AB Sciex QTRAP 4500 mass spectrometer equipped with a Turbo V ion source and a TurbolonSpray probe for electrospray ionization (AB Sciex, Framingham, MA, USA). Source parameters were set as follows: ion spray voltage, −4500 V; curtain gas, 30 psi; nebulizer gas, 50 psi; desolvation gas, 60 psi; temperature, 425 °C. Phospholipid species were analyzed in scheduled multiple-reaction monitoring mode with negative ionization, detecting the m/z of 253.2 in Q3, corresponding to palmitoleic acid as [M-H]–. Compound parameters were fixed as follows: declustering potential: −45 V (PC), −60 V (PE), −30 V (PI), −50 V (PS), −60 V (phosphatidic acid), −50 V (phosphatidylglycerol); collision energy: −50 V (PC), −40 V (PE), −60 V (PI), −50 V (PS), −45 V (phosphatidic acid), −45 V (phosphatidylglycerol); entrance potential: −10 V; and collision cell exit potential: −8 V. All phospholipid species were detected as [M-H]− ions except the PC species, which were detected as [M + CH3COO]− ions. Quantification was carried out by integrating the chromatographic peaks of each species and comparing with the peak area of the internal standard that corresponded to each class [29,52].

2.6. Statistical Analysis

The results are shown as mean ± standard error of the mean, and correspond to at least three independent determinations with incubations in duplicate. For statistical significance the data were analyzed with a t-test (two groups) or ANOVA (more than two groups), followed by Tukey’s post hoc test, using SigmaPlot software, version 14.0 (Systat Software Inc., San Jose, CA, USA). A value of p < 0.05 was considered statistically significant.

3. Results

Previous work from our laboratory has demonstrated the presence of significant amounts of POA in human monocytes, as well as its biological relevance as an anti-inflammatory lipid signal [25,26]. Figure 1A shows the mass distribution of POA among the various phospholipid classes of human monocytes, as measured by GC-MS. PC contained most of the POA present in these cells, amounting to approximately 70% of total cellular fatty acid. The POA content in other phospholipid classes was much lower. Next, the distribution of POA among the different phospholipid molecular species was determined by LC-MS, and the results are shown in Figure 1B. In these experiments, the molecular species of interest were unequivocally identified by multiple reaction monitoring experiments, where the fragment of m/z 253.2, which corresponds to the [M-H]− of the fatty acid, was detected in Q3. Following nomenclature recommendations, fatty chains within phospholipids are designated by their number of carbons:double bonds. A designation of O- before the first fatty chain indicates that the sn-1 position is ether-linked, whereas a P- designation indicates a plasmalogen form (sn-1 vinyl ether linkage) [53,54,55]. One single species, namely PC(16:0/16:1), contained almost one half of all cellular fatty acid (Figure 1B). All other major species were of the PC class. Not even one molecular species from the other classes (i.e., PE, PI, or PS) comprised more than 7% of total cellular fatty acid.
This propensity of POA to incorporate into choline-containing molecular species is striking and prompted us to characterize further the cellular mechanisms of phospholipid incorporation of POA in human monocytes, as well as the possible existence of fatty acid remodeling reactions between phospholipids. For these experiments, we used tritium-labeled POA, which improved sensitivity. Figure 2A shows that the exposure of the human monocytes to exogenous [3H]POA resulted in the rapid incorporation of the fatty acid into the different phospholipid classes. Consistent with its endogenous mass distribution, shown in Figure 1, [3H]POA incorporated primarily into PC, followed by PE, PI, and PS.
It is remarkable that in Figure 2A, the ratio of incorporation of the fatty acid into the various phospholipid classes was preserved at all time points, i.e., PC accounted for 60–70% of total fatty acid incorporation at all times tested, and the percent of label incorporated into PE, PI, and PS also remained the same at all times. These results suggest that, once incorporated into cellular phospholipids, POA is not further transferred between phospholipid classes by the actions of acyltransferases or transacylases. Thus, cells labeled for 24 h distribute the POA into phospholipid classes in a manner that represents the mass distribution (cf. Figure 1A and Figure 2A).
To confirm these findings, we conducted a pulse experiment where the monocytes were exposed to [3H]POA for 30 min, thoroughly washed to remove any unincorporated label, and then left in culture free of labeled fatty acid. Under these conditions, the relative distribution of the label between phospholipid classes was measured. Figure 2B shows that such a distribution did not vary with time; the fatty acid that was initially incorporated into either PC, PE, PI, or PS remained in its initial location. Thus, the distribution of POA was almost identical to that determined during the time-course experiment depicted in Figure 2A, and also very similar to that found for the endogenous preexisting fatty acid mass (Figure 1A). Collectively, these results suggest that the rate of incorporation of POA into the different classes of phospholipids does not change with time, and the fatty acid remains in the phospholipid class that initially incorporated it. This behavior contrasts with that of polyunsaturated fatty acids such as arachidonic acid (AA) [56,57,58,59], which are known to undergo profound remodeling between phospholipids that substantially changes their initial distribution [60,61,62].
In the next series of experiments, we investigated whether the cellular distribution of POA was affected by the activation state of the cells. For this purpose, we designed an experiment similar to the one described in Figure 2B, but in this case, after the initial labeling, the cells were exposed to yeast-derived zymosan. This compound has long been used as a model stimulus for the study of pathways involving fatty acid mobilization in monocytes and macrophages [63,64,65,66,67,68]. Zymosan induced a time-dependent decrease in the amount of [3H]POA in PC that was somewhat paralleled by an increase in the fatty acid in PI. No changes were detected in PE or PS (Figure 3A). To extend these observations to other monocyte activation conditions, these experiments were repeated utilizing the calcium ionophore A23187 as a stimulus. This compound is also widely used for studies assessing phospholipid fatty acid turnover in phagocytic cells [69,70,71,72,73]. The data in Figure 3B showed that the ionophore also reduced the content of POA in PC, while increasing it in PI.
LC-MS analyses of POA-containing phospholipid molecular species revealed significant decreases in the POA content of the major molecular species PC(16:0/16:1) in activated cells (Figure 4). A tendency for the minor species PC(18:1/16:1) to decrease was noted as well, but the difference failed to reach significance. On the other hand, two PI species whose POA levels increased after cell stimulation were clearly identified, i.e., PI(18:0/16:1) and PI(18:1/16:1) (Figure 4). In agreement with the data shown in Figure 3, no changes in the POA content of PE and PS could be detected (Figure 4).
To determine the cellular mechanisms underlying the changes in POA levels in PC and PI during cell activation, experiments using [3H]POA-labeled cells were conducted with triacsin C, an inhibitor of long-chain acyl-CoA synthetases [74,75,76]. Human monocytes are known to express all five forms of mammalian long-chain acyl-CoA synthetases, namely ACSL-1, -3, -4, -5, and -6 [30]. Of these, the triacsin C-sensitive forms are ACSL-1, -3, and -4, and previous studies have demonstrated that these are the major isoforms involved in the CoA-dependent regulation of fatty acid incorporation into phospholipids [77]. Notably, Figure 5 shows that triacsin C completely blocked the increased formation of POA-containing PI in the activated monocytes. Note, as well, that the decrease in POA levels in PC occurring as a consequence of monocyte activation was not blunted by triacsin C, suggesting that the release of POA from PC is due to the action of a bona fide phospholipase. In parallel experiments, we also tested the effect of SKF98625, an inhibitor of the CoA-independent transfer of polyunsaturated fatty acids between phospholipids in various cell types [78,79]. This compound exerted no discernible effects on POA levels in either PC or PI in the activated cells, as compared to the untreated cells.
Because POA has been shown to localize preferentially to the sn-2 position of the glycerol moiety of PC species in phagocytic cells [57], it appears logical to suggest that the phospholipase(s) involved in the liberation of POA from PC in monocytes is/are of the A2 type. Accordingly, in the next set of experiments we used a number of well-established inhibitors of the major cellular PLA2 forms potentially involved in fatty acid mobilization in activated cells. To inhibit the group IVA cytosolic phospholipase A2α (cPLA2α) we used pyrrophenone. This inhibitor potently and selectively blocks cPLA2α in cells without significantly affecting the activities of the other cellular phospholipase A2s [80,81,82]. To inhibit the activity of the multiple secreted phospholipase A2 (sPLA2) enzymes present in human leukocytes that are potentially capable of effecting the fatty acid release [83], we used the pan-sPLA2 inhibitor LY311727, an indomethacin analogue that blocks this kind of enzymes without exerting significant effects on other cellular phospholipase A2s [84,85,86]. To inhibit the group IVA calcium-independent PLA2 (iPLA2β), we used FKGK18, a fluoroketone that selectively inhibits iPLA2β in cells at concentrations at least 200-fold lower than those required to have an effect on either cPLA2α or sPLA2 [87,88]. For comparative purposes, we also used the structurally unrelated inhibitor bromoenol lactone (BEL) to inhibit cellular iPLA2β. This compound inhibits cellular calcium-independent PLA2 activity at concentrations at which calcium-dependent enzymes are not affected, although it may exert off-target effects depending on cell type and stimulation conditions [89,90,91].
Figure 6A shows that the inhibitors exerted disparate effects on the levels of POA in PC; while LY311727 had no discernible effect, both FKGK18 and BEL completely abrogated the zymosan-induced decrease in POA levels in PC. Consistent with these data, LY311727 had no effect on the zymosan-induced increases in POA levels in PI, while both FKGK18 and BEL completely blocked such increases. Collectively, these results indicate that sPLA2 enzymes do not participate in the stimulus-induced transfer of POA moieties for PC to PI. On the opposite side, the inhibition of iPLA2β results in the complete inhibition of POA repositioning between PC and PI in the activated cells, suggesting that this is the phospholipase that removes the POA from PC in order for it to be incorporated into PI later via CoA-dependent acyltransferases.
Of note, pyrrophenone treatment of the cells had no effect on the zymosan-induced POA decreases in PC (Figure 6A), yet the inhibitor completely blocked the stimulated formation of POA-containing PI (Figure 6B). These data suggest that there is a cPLA2α-sensitive step in the stimulated formation of POA-containing PI that is not related to the zymosan-induced changes in POA-containing PC.
Given that PI is particularly enriched with AA in phagocytic cells, including human monocytes [56,57,58], we reasoned that the stimulated formation of lysoPI that occurs as a by-product of the stimulus-induced cPLA2α-mediated AA mobilization [77,92,93] could represent the aforementioned step. In accordance with this view, zymosan-stimulated monocytes exhibited a time-dependent accumulation of the lysoPI molecular species LPI(18:0) and LPI(18:1), i.e., the two species incorporating elevated amounts of POA during zymosan stimulation (Figure 7A,B). Such an elevation was blunted by pyrrophenone (Figure 7D,G) but not by FKGK18 (Figure 7E,H).

4. Discussion

The present study examined the incorporation and remodeling of POA between phospholipid pools during the activation of human peripheral blood monocytes. In resting monocytes, POA incorporates primarily into PC, followed by PE, PI, and PS. This distribution does not change with time, i.e., the POA remains in the phospholipid class that initially incorporated it. Importantly, however, phospholipid fatty acid remodeling involving this fatty acid does occur after the cells are stimulated by either receptor-directed (zymosan) or soluble (calcium ionophore) agonists. Thus, there is a stimulated movement of POA moieties from PC to PI. While this transfer does not drastically change the distribution of POA among cellular phospholipids, i.e., PC still remains as the major POA-containing phospholipid in the cells, there is an enrichment with POA of two defined molecular species of PI, namely PI(18:0/16:1) and PI(18:1/16:1). Such enrichments increase the cellular mass of PI(18:0/16:1) and PI(18:1/16:1) by about 3.1- and 3.8-fold, respectively. Thus, it seems likely that these two species may play significant regulatory roles during the execution of cellular responses by the activated monocytes. Clearly, future work should be devoted to identifying cellular responses that imply these PI species, so that they can be included in the growing number of phospholipid molecular species with specific roles in stimulus–response coupling [94,95,96,97,98,99]. While addressing these cellular responses is beyond the scope of the current work, it is worth mentioning here that at least one of these species, namely PI(18:0/16:1), was described to possess growth-factor-like activity on fibroblasts [99]. More recently, the related species, PI(18:1/18:1), although lacking POA, was described to link the metabolism of unsaturated fatty acids with stress signaling [100].
Examination of the metabolic pathway regulating the increased formation of POA-containing molecular species in activated monocytes reveals that it proceeds through fatty acid recycling via phospholipase A2/CoA-dependent acyltransferases, i.e., the Lands cycle [101,102], rather than via CoA-independent, direct transfer of POA moieties between phospholipids, as occurs predominantly when the fatty acid to be remodeled is a polyunsaturate such as AA [60,61,62]. Importantly, the pathway appears to utilize two different phospholipase A2 enzymes; the first one provides the free fatty acid, and the second one provides the lysoPI acceptor (Figure 8). Thus, this route constitutes a prime example of the interaction of different phospholipase A2 enzymes, acting separately but in concert, within lipid signaling pathways. Utilizing different substrates, these phospholipase A2s contribute to generate lipid diversity, which may conceivably help the cell to respond properly to stimuli.
According to this pathway (Figure 8), POA is mobilized primarily from 1-palmitoyl-2-palmitoleoyl-glycero-3-phosphocholine (PC(16:0/16:1)) by iPLA2β. In parallel, cPLA2α hydrolyzes the arachidonate-containing PI species 1-stearoyl-2-arachidonoyl-glycero-3-phosphoinositol (PI(18:0/20:4)) and 1-oleoyl-2-arachidonoyl-glycero-3-phosphoinositol (PI(18:1/20:4)) to produce the corresponding lysophospholipids, LPI(18:0) and LPI(18:1). Acyl-CoA synthetases (ACSL) generate palmitoleoyl-CoA, which will be used by CoA-dependent acyltransferases (LPIAT) to form PI(18:0/16:1) and PI(18:1/16:1).
Although the movement of POA between PC and PI appears to be a quantitatively important process, it is also certainly possible that other reactions may also occur at the same time. Our earlier studies showed that POA tends to accumulate in neutral lipids when the monocytes transition into foamy cells [30] and, in murine peritoneal macrophages, POA is used for the formation of the anti-inflammatory branched ester palmitoleyl hydroxystearate [29]. We have not detected these reactions in the human monocytes, which is probably due, on one hand, to the fact that human monocytes contain lesser amounts of POA than murine peritoneal macrophages [26] and, on the other hand, to cell type differences arising from specialized roles in physiology and pathophysiology.
The involvement of iPLA2β as the initiating enzyme in the pathway leading to the elevated formation of POA-enriched PI species is of special interest. Unlike other members of the phospholipase A2 superfamily, such as the sPLA2s or cPLA2α, iPLA2β appears to lack an ‘activating switch’ that increases its cellular activity after stimulation, either by increasing the enzyme mass or the intrinsic enzyme activity [89,90,91]. While iPLA2β manifests no evident substrate preference when its activity is determined in in vitro assays [103,104,105], studies with primary cell cultures, iPLA2β-overexpressing cells, or cells from iPLA2β knock-out animals have established that iPLA2β manifests in cells a clear preference for hydrolyzing PC species containing palmitic acid at the sn-1 position [57,106,107,108,109,110]. This is in perfect agreement with the data of this study, and aligns with our hypothesis that the substrate specificities of phospholipase A2 enzymes, as observed in vivo, may be constrained by their subcellular localization [111]. Substrate compartmentalization may therefore constitute a major mechanism for the cellular regulation of iPLA2β activity on membrane phospholipids [111].
While a large number of studies on phospholipid fatty acid remodeling have focused on the exchange of polyunsaturated fatty acids mainly between PC and PE [60,61,62,77], it seems likely that PI species may also actively participate in lipid membrane modulation. Thus, an intriguing possibility that stems from the data presented in this study is whether fatty acid transfer from PC to PI is bidirectional, i.e., whether part of the AA released from PI by cPLA2α in the activated cells may be reacylated into PC to compensate, at least in part, the POA lost from PC through the action of iPLA2β. This attractive possibility cannot be directly tested in a study such as this one, which deals with live cells, because it is not possible to distinguish the PI-bound AA from the same fatty acid that is already present in PC which, to compound, represents a larger pool [112]. Studies with different cell types such as human neutrophils or murine macrophages have provided support to the concept that specific phospholipid pools are linked to the formation of particular eicosanoids, with PC likely playing a major role [57,59,113,114,115,116]. In addition, it is worth remarking that zymosan-stimulated AA mobilization in human monocytes, which involves the hydrolysis of both PC and PI, is not altered by the BEL inhibition of iPLA2β [35]. The latter condition is shown in this study to result in the diminished mobilization of POA from PC.

5. Conclusions

In this work, we show that remodeling of POA between phospholipid molecular species occurs in activated human monocytes. The process, which is CoA-dependent, involves the participation of two different intracellular phospholipase A2s acting in concert but separately to provide the free POA, on one hand, and the lysophospholipid acceptor on the other. By using mass spectrometry, we identified the major provider of POA as the molecular species PC(16:0/16:1), and two PI molecular species, namely PI(18:0/16:1) and PI(18:1/16:1), as major products within this remodeling pathway. It seems likely that accumulation of POA in defined PI species during the activation of human monocytes may underlie some of the biological effects attributed to this fatty acid.

Author Contributions

Conceptualization, J.B.; Formal analysis, M.A.B. (Miguel A. Bermúdez), A.G., L.P., T.G., M.A.B. (María A. Balboa) and J.B.; Funding acquisition, M.A.B. (María A. Balboa) and J.B.; Investigation, M.A.B. (Miguel A. Bermúdez), A.G., L.P. and T.G.; Methodology, M.A.B. (Miguel A. Bermúdez), A.G., L.P. and T.G.; Project administration, M.A.B. (María A. Balboa) and J.B.; Supervision, M.A.B. (María A. Balboa); Writing—original draft, J.B.; Writing—review and editing, M.A.B. (Miguel A. Bermúdez), A.G., L.P., M.A.B. (María A. Balboa) and J.B. All authors have read and agreed to the published version of the manuscript.

Funding

This research was supported by grants PID2019-105989RB-I00 and PID2022-140764OB-I00, funded by the Spanish Ministry of Science, Innovation, and Universities, Agencia Estatal de Investigación (MICIN/AEI/10.13039/501100011033) and the European Union through the European Regional Development Fund, “A Way of Making Europe”, and by grant CB07/08/0004 from CIBERDEM-Instituto de Salud Carlos III. The APC was funded by the Spanish National Research Council (CSIC).

Institutional Review Board Statement

This study was approved by the Institutional Review Board of the Regional Center for Hemotherapy and Blood Donation of Castile and Leon (approval code: IBGM-JB-16-01; approval date: 3 November 2019, renewed: 22 December 2022), and the Ethics and Bioethics Committee of the Spanish National Research Council (approval code: 101/2019; approval date: 26 February 2020).

Informed Consent Statement

Written informed consent was obtained from each donor.

Data Availability Statement

Data are contained within the article.

Acknowledgments

We thank the members of the Balsinde and Balboa labs, past and present, for helpful discussions regarding these data.

Conflicts of Interest

The authors declare no conflicts of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript; or in the decision to publish the results.

Abbreviations

POApalmitoleic acid (cis-9-hexadecenoic acid, 16:1n–7)
AAarachidonic acid (cis-5,8,11,14-eicosatetraenoic acid, 20:4n–6)
PCphosphatidylcholine
PEphosphatidylethanolamine
PIphosphatidylinositol
PSphosphatidylserine
cPLA2αgroup IVA cytosolic phospholipase A2α
iPLA2βgroup VIA calcium-independent phospholipase A2
sPLA2secreted phospholipase A2

References

  1. Franz, M.J. Weight management: Obesity to diabetes. Diabetes Spctr. 2017, 30, 149–153. [Google Scholar] [CrossRef] [PubMed]
  2. Piché, M.E.; Tchernof, A.; Després, J.P. Obesity phenotypes, diabetes, and cardiovascular diseases. Circ. Res. 2020, 126, 1477–1500. [Google Scholar] [CrossRef] [PubMed]
  3. Wyatt, S.B.; Winters, K.P.; Dubbert, P.M. Overweight and obesity: Prevalence, consequences, and causes of a growing public health problem. Am. J. Med. Sci. 2006, 331, 166–174. [Google Scholar] [CrossRef] [PubMed]
  4. Hotamisligil, G.S. Inflammation, metaflammation and immunometabolic disorders. Nature 2017, 542, 177–185. [Google Scholar] [CrossRef]
  5. Moore, K.J.; Tabas, I. Macrophages in the pathogenesis of atherosclerosis. Cell 2011, 145, 341–355. [Google Scholar] [CrossRef] [PubMed]
  6. Tabas, I.; Bornfeldt, K.E. Macrophage phenotype and function in different stages of atherosclerosis. Circ. Res. 2016, 118, 653–667. [Google Scholar] [CrossRef]
  7. Li, H.; Meng, Y.; He, S.; Tan, X.; Zhang, Y.; Zhang, X.; Wang, L.; Zheng, W. Macrophages, chronic inflammation, and insulin resistance. Cells 2022, 11, 3001. [Google Scholar] [CrossRef]
  8. Russo, S.; Kwiatkowski, M.; Govorukhina, N.; Bischoff, R.; Melgert, B.N. Meta-inflammation and metabolic reprogramming of macrophages in diabetes and obesity: The importance of metabolites. Front. Immunol. 2021, 12, 746151. [Google Scholar] [CrossRef]
  9. Lauterbach, M.A.; Wunderlich, F.T. Macrophage function in obesity-induced inflammation and insulin resistance. Pflugers Arch. 2017, 469, 385–396. [Google Scholar] [CrossRef]
  10. Mukherjee, S.; Skrede, S.; Haugstøyl, M.; López, M.; Fernø, J. Peripheral and central macrophages in obesity. Front. Endocrinol. 2023, 14, 1232171. [Google Scholar] [CrossRef]
  11. Chavakis, T.; Alexaki, V.I.; Ferrante, A.W., Jr. Macrophage function in adipose tissue homeostasis and metabolic inflammation. Nat. Immunol. 2023, 24, 757–766. [Google Scholar] [CrossRef] [PubMed]
  12. Santa-María, C.; López-Enríquez, S.; Montserrat-de la Paz, S.; Geniz, I.; Reyes-Quiroz, M.E.; Moreno, M.; Palomares, F.; Sobrino, F.; Alba, G. Update on anti-inflammatory molecular mechanisms induced by oleic acid. Nutrients 2023, 15, 224. [Google Scholar] [CrossRef] [PubMed]
  13. López, S.; Bermúdez, B.; Montserrat-de la Paz, S.; Jaramillo, S.; Varela, L.M.; Ortega-Gómez, A.; Abia, R.; Muriana, F.J.G. Membrane composition and dynamics: A target of bioactive virgin olive oil constituents. Biochim. Biophys. Acta 2014, 1838, 1638–1656. [Google Scholar] [CrossRef] [PubMed]
  14. Dernini, S.; Berry, E.M. Mediterranean diet: From a healthy diet to a sustainable dietary pattern. Front. Nutr. 2015, 2, 15. [Google Scholar] [CrossRef] [PubMed]
  15. Schwingshackl, L.; Hoffmann, G. Monounsaturated fatty acids and risk of cardiovascular disease: Synopsis of the evidence available from systematic reviews and meta-analyses. Nutrients 2012, 4, 1989–2007. [Google Scholar] [CrossRef] [PubMed]
  16. Cao, H.; Gerhold, K.; Mayers, J.R.; Wiest, M.M.; Watkins, S.M.; Hotamisligil, G.S. Identification of a lipokine, a lipid hormone 440 linking adipose tissue to systemic metabolism. Cell 2008, 134, 933–944. [Google Scholar] [CrossRef] [PubMed]
  17. Erbay, E.; Babaev, V.R.; Mayers, J.R.; Makowski, L.; Charles, K.N.; Snitow, M.E.; Fazio, S.; Wiest, M.M.; Watkins, S.M.; Linton, M.F.; et al. Reducing endoplasmic reticulum stress through a macrophage lipid chaperone alleviates atherosclerosis. Nat. Med. 2009, 15, 1383–1391. [Google Scholar] [CrossRef] [PubMed]
  18. Cetin, E.; Pedersen, B.; Porter, L.M.; Adler, G.K.; Burak, M.F. Protocol for a randomized placebo-controlled clinical trial using pure palmitoleic acid to ameliorate insulin resistance and lipogenesis in overweight and obese subjects with prediabetes. Front. Endocrinol. 2024, 14, 1306528. [Google Scholar] [CrossRef]
  19. de Souza, C.O.; Vannice, G.K.; Rosa Neto, J.C.; Calder, P.C. Is palmitoleic acid a plausible nonpharmacological strategy to 482 prevent or control chronic metabolic and inflammatory disorders? Mol. Nutr. Food Res. 2018, 62, 1700504. [Google Scholar] [CrossRef]
  20. Bermúdez, M.A.; Pereira, L.; Fraile, C.; Valerio, L.; Balboa, M.A.; Balsinde, J. Roles of palmitoleic acid and its positional isomers, hypogeic and sapienic acids, in inflammation, metabolic diseases and cancer. Cells 2022, 11, 2146. [Google Scholar] [CrossRef]
  21. Chan, K.L.; Pillon, N.J.; Sivaloganathan, D.M.; Costford, S.R.; Liu, Z.; Théret, M.; Chazaud, B.; Klip, A. Palmitoleate reverses high fat-induced proinflammatory macrophage polarization via AMP-activated protein kinase. J. Biol. Chem. 2015, 290, 16979–16988. [Google Scholar] [CrossRef] [PubMed]
  22. de Souza, C.O.; Valenzuela, C.A.; Baker, E.J.; Miles, E.A.; Rosa Neto, J.C.; Calder, P.C. Palmitoleic acid has stronger anti-in-flammatory potential in human endothelial cells compared to oleic and palmitic acids. Mol. Nutr. Food Res. 2018, 62, e1800322. [Google Scholar] [CrossRef] [PubMed]
  23. Souza, C.O.; Teixeira, A.A.S.; Biondo, L.A.; Silveira, L.S.; de Souza Breda, C.N.; Braga, T.T.; Camara, N.O.S.; Belchior, T.; Festuccia, W.T.; Diniz, T.A.; et al. Palmitoleic acid reduces high fat diet-induced liver inflammation by promoting PPAR-γ-independent M2a polarization of myeloid cells. Biochim. Biophys. Acta 2020, 1865, 158776. [Google Scholar] [CrossRef] [PubMed]
  24. Tsai, Y.W.; Lu, C.H.; Chang, R.C.; Hsu, Y.P.; Ho, L.T.; Shih, K.C. Palmitoleic acid ameliorates palmitic acid-induced proinflammation in J774A.1 macrophages via TLR4-dependent and TNF-alpha-independent signallings. Prostag. Leukot. Essent. Fatty Acids 2021, 169, 102270. [Google Scholar] [CrossRef] [PubMed]
  25. Guijas, C.; Meana, C.; Astudillo, A.M.; Balboa, M.A.; Balsinde, J. Foamy monocytes are enriched in cis-7-hexadecenoic fatty acid (16:1n-9), a possible biomarker for early detection of cardiovascular disease. Cell Chem. Biol. 2016, 23, 689–699. [Google Scholar] [CrossRef] [PubMed]
  26. Astudillo, A.M.; Meana, C.; Guijas, C.; Pereira, L.; Lebrero, R.; Balboa, M.A.; Balsinde, J. Occurrence and biological activity of palmitoleic acid isomers in phagocytic cells. J. Lipid Res. 2018, 59, 237–249. [Google Scholar] [CrossRef] [PubMed]
  27. Ntambi, J.M.; Miyazaki, M. Regulation of stearoyl-CoA desaturases and role in metabolism. Prog. Lipid Res. 2004, 43, 91–104. [Google Scholar] [CrossRef]
  28. Kamal, S.; Saleem, A.; Rehman, S.; Bibi, I.; Iqbal, H.M.N. Protein engineering: Regulatory perspectives of stearoyl CoA desaturase. Int. J. Biol. Macromol. 2018, 114, 692–699. [Google Scholar] [CrossRef]
  29. Astudillo, A.M.; Meana, C.; Bermúdez, M.A.; Pérez-Encabo, A.; Balboa, M.A.; Balsinde, J. Release of anti-inflammatory palmitoleic acid and its positional isomers by mouse peritoneal macrophages. Biomedicines 2020, 8, 480. [Google Scholar] [CrossRef]
  30. Guijas, C.; Pérez-Chacón, G.; Astudillo, A.M.; Rubio, J.M.; Gil-de-Gómez, L.; Balboa, M.A.; Balsinde, J. Simultaneous activation of p38 and JNK by arachidonic acid stimulates the cytosolic phospholipase A2-dependent synthesis of lipid droplets in human monocytes. J. Lipid Res. 2012, 53, 2343–2354. [Google Scholar] [CrossRef]
  31. Yore, M.M.; Syed, I.; Moraes-Vieira, P.M.; Zhang, T.; Herman, M.A.; Homan, E.A.; Patel, R.T.; Lee, J.; Chen, S.; Peroni, O.D.; et al. Discovery of a class of endogenous mammalian lipids with anti-diabetic and anti-inflammatory effects. Cell 2014, 159, 318–332. [Google Scholar] [CrossRef] [PubMed]
  32. Brejchova, K.; Balas, L.; Paluchova, V.; Brezinova, M.; Durand, T.; Kuda, O. Understanding FAHFAs: From structure to metabolic regulation. Prog. Lipid Res. 2020, 79, 101053. [Google Scholar] [CrossRef] [PubMed]
  33. Seno, K.; Okuno, T.; Nishi, K.; Murakami, Y.; Yamada, K.; Nakamoto, S.; Ono, T. Pyrrolidine inhibitors of human cytosolic phospholipase A2. Synthesis of potent and crystallized 4-triphenylmethylthio derivative ‘pyrrophenone’. Bioorg. Med. Chem. Lett. 2001, 11, 587–590. [Google Scholar] [CrossRef] [PubMed]
  34. Chilton, F.H.; Fonteh, A.N.; Sung, C.M.; Hickey, D.M.; Torphy, T.J.; Mayer, R.J.; Marshall, L.A.; Heravi, J.D.; Winkler, J.D. Inhibitors of CoA-independent transacylase block the movement of arachidonate into 1-ether-linked phospholipids of human neutrophils. Biochemistry 1995, 34, 5403–5410. [Google Scholar] [CrossRef] [PubMed]
  35. Pérez-Chacón, G.; Astudillo, A.M.; Ruipérez, V.; Balboa, M.A.; Balsinde, J. Signaling role for lysophospholipid acyltransferase 3 in receptor-regulated arachidonic acid reacylation reactions in human monocytes. J. Immunol. 2010, 184, 1071–1078. [Google Scholar] [CrossRef] [PubMed]
  36. Rubio, J.M.; Rodríguez, J.P.; Gil-de-Gómez, L.; Guijas, C.; Balboa, M.A.; Balsinde, J. Group V secreted phospholipase A2 is up-regulated by interleukin-4 in human macrophages and mediates phagocytosis via hydrolysis of ethanolamine phospholipids. J. Immunol. 2015, 194, 3327–3339. [Google Scholar] [CrossRef] [PubMed]
  37. Balsinde, J.; Balboa, M.A.; Dennis, E.A. Identification of a third pathway for arachidonic acid mobilization and prostaglandin production in activated P388D1 macrophage-like cells. J. Biol. Chem. 2000, 275, 22544–22549. [Google Scholar] [CrossRef] [PubMed]
  38. Balboa, M.A.; Pérez, R.; Balsinde, J. Amplification mechanisms of inflammation: Paracrine stimulation of arachidonic acid mobilization by secreted phospholipase A2 is regulated by cytosolic phospholipase A2-derived hydroperoxyeicosatetraenoic acid. J. Immunol. 2003, 171, 989–994. [Google Scholar] [CrossRef]
  39. Balboa, M.A.; Sáez, Y.; Balsinde, J. Calcium-independent phospholipase A2 is required for lysozyme secretion in U937 promonocytes. J. Immunol. 2003, 170, 5276–5280. [Google Scholar] [CrossRef]
  40. Balsinde, J.; Balboa, M.A.; Insel, P.A.; Dennis, E.A. Differential regulation of phospholipase D and phospholipase A2 by protein kinase C in P388D1 macrophages. Biochem. J. 1997, 321, 805–809. [Google Scholar] [CrossRef]
  41. Bradford, M.M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 1976, 72, 248–254. [Google Scholar] [CrossRef] [PubMed]
  42. Bligh, E.G.; Dyer, W.J. A rapid method of total lipid extraction and purification. Can. J. Biochem. Physiol. 1959, 37, 911–917. [Google Scholar] [CrossRef] [PubMed]
  43. Diez, E.; Balsinde, J.; Aracil, M.; Schüller, A. Ethanol induces release of arachidonic acid but not synthesis of eicosanoids in mouse peritoneal macrophages. Biochim. Biophys. Acta 1987, 921, 82–89. [Google Scholar] [CrossRef] [PubMed]
  44. Fine, J.B.; Sprecher, H. Unidimensional thin-layer chromatography of phospholipids on boric acid-impregnated plates. J. Lipid Res. 1982, 23, 660–663. [Google Scholar] [CrossRef] [PubMed]
  45. Xu, G.; Waki, H.; Kon, K.; Ando, S. Thin-layer chromatography of phospholipids and their lyso forms: Application to determination of extracts from rat hippocampal CA1 region. Microchem. J. 1996, 53, 29–33. [Google Scholar] [CrossRef]
  46. Fuchs, B.; Süss, R.; Teuber, K.; Eibisch, M.; Schiller, J. Lipid analysis by thin-layer chromatography—A review of the current state. J. Chromatogr. A 2011, 1218, 2754–2774. [Google Scholar] [CrossRef] [PubMed]
  47. Pérez, R.; Matabosch, X.; Llebaria, A.; Balboa, M.A.; Balsinde, J. Blockade of arachidonic acid incorporation into phospholipids induces apoptosis in U937 promonocytic cells. J. Lipid Res. 2006, 47, 484–491. [Google Scholar] [CrossRef]
  48. Lebrero, P.; Astudillo, A.M.; Rubio, J.M.; Fernández-Caballero, J.; Kokotos, G.; Balboa, M.A.; Balsinde, J. Cellular plasmalogen content does not influence arachidonic acid levels or distribution in macrophages: A role for cytosolic phospholipase A2γ in phospholipid remodeling. Cells 2019, 8, 799. [Google Scholar] [CrossRef] [PubMed]
  49. Astudillo, A.M.; Pérez-Chacón, G.; Balgoma, D.; Gil-de-Gómez, L.; Ruipérez, V.; Guijas, C.; Balboa, M.A.; Balsinde, J. Influence of cellular arachidonic acid levels on phospholipid remodeling and CoA-independent transacylase activity in human monocytes and U937 cells. Biochim. Biophys. Acta 2011, 1811, 97–103. [Google Scholar] [CrossRef]
  50. Rodríguez, J.P.; Guijas, C.; Astudillo, A.M.; Rubio, J.M.; Balboa, M.A.; Balsinde, J. Sequestration of 9-hydroxystearic acid in FAHFA (fatty acid esters of hydroxy fatty acids) as a protective mechanism for colon carcinoma cells to avoid apoptotic cell death. Cancers 2019, 11, 524. [Google Scholar] [CrossRef]
  51. Axelsen, P.H.; Murphy, R.C. Quantitative analysis of phospholipids containing arachidonate and docosahexaenoate chains in microdissected regions of mouse brain. J. Lipid Res. 2010, 51, 660–671. [Google Scholar] [CrossRef] [PubMed]
  52. Monge, P.; Garrido, A.; Rubio, J.M.; Magrioti, V.; Kokotos, G.; Balboa, M.A.; Balsinde, J. The contribution of cytosolic group IVA and calcium-independent group VIA phospholipase A2s to adrenic acid mobilization in murine macrophages. Biomolecules 2020, 10, 542. [Google Scholar] [CrossRef] [PubMed]
  53. Fahy, E.; Subramaniam, S.; Brown, H.A.; Glass, C.K.; Merrill, A.H., Jr.; Murphy, R.C.; Raetz, C.R.; Russell, D.W.; Seyama, Y.; Shaw, W.; et al. A comprehensive classification system for lipids. J. Lipid Res. 2005, 46, 839–861. [Google Scholar] [CrossRef] [PubMed]
  54. Fahy, E.; Subramaniam, S.; Murphy, R.C.; Nishijima, M.; Raetz, C.R.; Shimizu, T.; Spener, F.; van Meer, G.; Wakelam, M.J.; Dennis, E.A. Update of the LIPID MAPS comprehensive classification system for lipids. J. Lipid Res. 2009, 50, S9–S14. [Google Scholar] [CrossRef]
  55. Liebisch, G.; Fahy, E.; Aoki, J.; Dennis, E.A.; Durand, T.; Ejsing, C.S.; Fedorova, M.; Feussner, I.; Griffiths, W.J.; Köfeler, H.; et al. Update on LIPID MAPS classification, nomenclature, and shorthand notation for MS-derived lipid structures. J. Lipid Res. 2020, 61, 1539–1555. [Google Scholar] [CrossRef] [PubMed]
  56. Balgoma, D.; Astudillo, A.M.; Pérez-Chacón, G.; Montero, O.; Balboa, M.A.; Balsinde, J. Markers of monocyte activation revealed by lipidomic profiling of arachidonic acid-containing phospholipids. J. Immunol. 2010, 184, 3857–3865. [Google Scholar] [CrossRef] [PubMed]
  57. Gil-de-Gómez, L.; Astudillo, A.M.; Guijas, C.; Magrioti, V.; Kokotos, G.; Balboa, M.A.; Balsinde, J. Cytosolic group IVA and calcium-independent group VIA phospholipase A2s act on distinct phospholipid pools in zymosan-stimulated mouse peritoneal macrophages. J. Immunol. 2014, 192, 752–762. [Google Scholar] [CrossRef] [PubMed]
  58. Rubio, J.M.; Astudillo, A.M.; Casas, J.; Balboa, M.A.; Balsinde, J. Regulation of phagocytosis in macrophages by membrane ethanolamine plasmalogens. Front. Immunol. 2018, 9, 1723. [Google Scholar] [CrossRef] [PubMed]
  59. Rouzer, C.A.; Ivanova, P.T.; Byrne, M.O.; Milne, S.B.; Brown, H.A.; Marnett, L.J. Lipid profiling reveals glycerophospholipid remodeling in zymosan-stimulated macrophages. Biochemistry 2007, 46, 6026–6042. [Google Scholar] [CrossRef]
  60. MacDonald, J.I.; Sprecher, H. Phospholipid fatty acid remodeling in mammalian cells. Biochim. Biophys. Acta 1991, 1084, 105–121. [Google Scholar] [CrossRef]
  61. Chilton, F.H.; Fonteh, A.N.; Surette, M.E.; Triggiani, M.; Winkler, J.D. Control of arachidonate levels within inflammatory cells. Biochim. Biophys. Acta 1996, 1299, 1–15. [Google Scholar] [CrossRef] [PubMed]
  62. Yamashita, A.; Hayashi, Y.; Nemoto-Sasaki, Y.; Ito, M.; Oka, S.; Tanikawa, T.; Waku, K.; Sugiura, T. Acyltransferases and transacylases that determine the fatty acid composition of glycerolipids and the metabolism of bioactive lipid mediators in mammalian cells and model organisms. Prog. Lipid Res. 2014, 53, 18–81. [Google Scholar] [CrossRef] [PubMed]
  63. Humes, J.L.; Bonney, R.J.; Pelus, L.; Dahlgren, M.E.; Sadowski, S.J.; Kuehl, F.A.; Davies, P. Macrophages synthesise and release prostaglandins in response to inflammatory stimuli. Nature 1977, 269, 149–151. [Google Scholar] [CrossRef] [PubMed]
  64. Scott, W.A.; Zrike, J.M.; Hamill, A.L.; Kempe, J.; Cohn, Z.A. Regulation of arachidonic acid metabolites in macrophages. J. Exp. Med. 1980, 152, 324–335. [Google Scholar] [CrossRef] [PubMed]
  65. Emilsson, A.; Sundler, R. Evidence for a catalytic role of phospholipase A in phorbol diester- and zymosan-induced mobilization of arachidonic acid in mouse peritoneal macrophages. Biochim. Biophys. Acta 1986, 876, 533–542. [Google Scholar] [CrossRef] [PubMed]
  66. Balsinde, J.; Fernández, B.; Solís-Herruzo, J.A.; Diez, E. Pathways for arachidonic acid mobilization in zymosan-stimulated mouse peritoneal macrophages. Biochim. Biophys. Acta 1992, 1136, 75–82. [Google Scholar] [CrossRef] [PubMed]
  67. Qiu, Z.H.; Leslie, C.C. Protein kinase C-dependent and -independent pathways of mitogen-activated protein kinase activation in macrophages by stimuli that activate phospholipase A2. J. Biol Chem. 1994, 269, 19480–19487. [Google Scholar] [CrossRef]
  68. Satake, Y.; Diaz, B.L.; Balestrieri, B.; Lam, B.K.; Kanaoka, Y.; Grusby, M.J.; Arm, J.P. Role of group V phospholipase A2 in zymosan-induced eicosanoid generation and vascular permeability revealed by targeted gene disruption. J. Biol. Chem. 2004, 279, 16488–16494. [Google Scholar] [CrossRef] [PubMed]
  69. Emilsson, A.; Sundler, R. Differential activation of phosphatidylinositol deacylation and a pathway via diphosphoinositide in macrophages responding to zymosan and ionophore A23187. J. Biol. Chem. 1984, 259, 3111–3116. [Google Scholar] [CrossRef]
  70. Hoffman, T.; Lizzio, E.F.; Suissa, J.; Rotrosen, D.; Sullivan, J.A.; Mandell, G.L.; Bonvini, E. Dual stimulation of phospholipase activity in human monocytes. Role of calcium-dependent and calcium-independent pathways in arachidonic acid release and eicosanoid formation. J. Immunol. 1988, 140, 3912–3918. [Google Scholar] [CrossRef]
  71. Balsinde, J.; Fernández, B.; Diez, E. Regulation of arachidonic acid release in mouse peritoneal macrophages. The role of extracellular calcium and protein kinase C. J. Immunol. 1990, 144, 4298–4304. [Google Scholar] [CrossRef] [PubMed]
  72. Gijón, M.A.; Spencer, D.M.; Siddiqi, A.R.; Bonventre, J.V.; Leslie, C.C. Cytosolic phospholipase A2 is required for macrophage arachidonic acid release by agonists that do and do not mobilize calcium. J. Biol. Chem. 2000, 275, 20146–20156. [Google Scholar] [CrossRef] [PubMed]
  73. Shirai, Y.; Balsinde, J.; Dennis, E.A. Localization and functional interrelationships among cytosolic group IV, secreted group V, and Ca2+-independent group VI phospholipase A2s in P388D1 macrophages using GFP/RFP constructs. Biochim. Biophys. Acta 2005, 1735, 119–129. [Google Scholar] [CrossRef]
  74. Hartman, E.J.; Omura, S.; Laposata, M. Triacsin C: A differential inhibitor of arachidonoyl-CoA synthetase and nonspecific long chain acyl-CoA synthetase. Prostaglandins 1989, 37, 655–671. [Google Scholar] [CrossRef]
  75. Kim, J.H.; Lewin, T.M.; Coleman, R.A. Expression and characterization of recombinant rat acyl-CoA synthetases 1, 4, and 5. Selective inhibition by triacsin C and thiazolidinediones. J. Biol. Chem. 2001, 276, 24667–24673. [Google Scholar] [CrossRef] [PubMed]
  76. Vessey, D.A.; Kelley, M.; Warren, R.S. Characterization of triacsin C inhibition of short-, medium-, and long-chain fatty acid: CoA ligases of human liver. J. Biochem. Mol. Toxicol. 2004, 18, 100–106. [Google Scholar] [CrossRef]
  77. Pérez-Chacón, G.; Astudillo, A.M.; Balgoma, D.; Balboa, M.A.; Balsinde, J. Control of free arachidonic acid levels by phospholipases A2 and lysophospholipid acyltransferases. Biochim. Biophys. Acta 2009, 1791, 1103–1113. [Google Scholar] [CrossRef] [PubMed]
  78. Winkler, J.D.; Fonteh, A.N.; Sung, C.M.; Heravi, J.D.; Nixon, A.B.; Chabot-Fletcher, M.; Griswold, D.E.; Marshall, L.A.; Chilton, F.H. Effects of CoA-independent transacylase inhibitors on the production of lipid inflammatory mediators. J. Pharmacol. Exp. Ther. 1995, 274, 1338–1347. [Google Scholar]
  79. Winkler, J.D.; Eris, T.; Sung, C.M.; Chabot-Fletcher, M.; Mayer, R.J.; Surette, M.E.; Chilton, F.H. Inhibitors of coenzyme A-independent transacylase induce apoptosis in human HL-60 cells. J. Pharmacol. Exp. Ther. 1996, 279, 956–966. [Google Scholar]
  80. Ono, T.; Yamada, K.; Chikazawa, Y.; Ueno, M.; Nakamoto, S.; Okuno, T.; Seno, K. Characterization of a novel inhibitor of cytosolic phospholipase A2α, pyrrophenone. Biochem. J. 2002, 363, 727–735. [Google Scholar] [CrossRef]
  81. Ghomashchi, F.; Stewart, A.; Hefner, Y.; Ramanadham, S.; Turk, J.; Leslie, C.C.; Gelb, M.H. A pyrrolidine-based specific inhibitor of cytosolic phospholipase A2α blocks arachidonic acid release in a variety of mammalian cells. Biochim. Biophys. Acta 2001, 1513, 160–166. [Google Scholar] [CrossRef] [PubMed]
  82. Flamand, N.; Picard, S.; Lemieux, L.; Pouliot, M.; Bourgoin, S.G.; Borgeat, P. Effects of pyrrophenone, an inhibitor of group IVA phospholipase A2, on eicosanoid and PAF biosynthesis in human neutrophils. Br. J. Pharmacol. 2006, 149, 385–392. [Google Scholar] [CrossRef] [PubMed]
  83. Degousee, N.; Ghomashchi, F.; Stefanski, E.; Singer, A.G.; Smart, B.P.; Borregaard, N.; Reithmeier, R.; Lindsay, T.F.; Lichtenberger, C.; Reinisch, W.; et al. Groups IV, V, and X phospholipases A2s in human neutrophils: Role in eicosanoid production and gram-negative bacterial phospholipid hydrolysis. J. Biol. Chem. 2002, 277, 5061–5073. [Google Scholar] [CrossRef] [PubMed]
  84. Schevitz, R.W.; Bach, N.J.; Carlson, D.G.; Chirgadze, N.Y.; Clawson, D.K.; Dillard, R.D.; Draheim, S.E.; Hartley, L.W.; Jones, N.D.; Mihelich, E.D.; et al. Structure-based design of the first potent and selective inhibitor of human non-pancreatic secretory phospholipase A2. Nat. Struct. Biol. 1995, 2, 458–465. [Google Scholar] [CrossRef] [PubMed]
  85. Thommesen, L.; Sjursen, W.; Gåsvik, K.; Hanssen, W.; Brekke, O.L.; Skattebøl, L.; Holmeide, A.K.; Espevik, T.; Johansen, B.; Lægreid, A. Selective inhibitors of cytosolic or secretory phospholipase A2 block TNF-induced activation of transcription factor nuclear factor-κB and expression of ICAM-1. J. Immunol. 1998, 161, 3421–3430. [Google Scholar] [CrossRef] [PubMed]
  86. Balsinde, J.; Balboa, M.A.; Yedgar, S.; Dennis, E.A. Group V phospholipase A2-mediated oleic acid mobilization in lipopolysaccharide-stimulated P388D1 macrophages. J. Biol. Chem. 2000, 275, 4783–4786. [Google Scholar] [CrossRef] [PubMed]
  87. Kokotos, G.; Hsu, Y.H.; Burke, J.E.; Baskakis, C.; Kokotos, C.G.; Magrioti, V.; Dennis, E.A. Potent and selective fluoroketone inhibitors of group VIA calcium-independent phospholipase A2. J. Med. Chem. 2010, 53, 3602–3610. [Google Scholar] [CrossRef] [PubMed]
  88. Ali, T.; Kokotos, G.; Magrioti, V.; Bone, R.N.; Mobley, J.A.; Hancock, W.; Ramanadham, S. Characterization of FKGK18 as inhibitor of group VIA Ca2+-independent phospholipase A2 (iPLA2β): Candidate drug for preventing beta-cell apoptosis and diabetes. PLoS ONE 2013, 8, e71748. [Google Scholar] [CrossRef] [PubMed]
  89. Balsinde, J.; Balboa, M.A. Cellular regulation and proposed biological functions of group VIA calcium-independent phospholipase A2 in activated cells. Cell. Signal. 2005, 17, 1052–1062. [Google Scholar] [CrossRef]
  90. Dennis, E.A.; Cao, J.; Hsu, Y.H.; Magrioti, V.; Kokotos, G. Phospholipase A2 enzymes: Physical structure, biological function, disease implication, chemical inhibition, and therapeutic intervention. Chem. Rev. 2011, 111, 6130–6185. [Google Scholar] [CrossRef]
  91. Ramanadham, S.; Ali, T.; Ashley, J.W.; Bone, R.N.; Hancock, W.D.; Lei, X. Calcium-independent phospholipases A2 and their roles in biological processes and diseases. J. Lipid Res. 2015, 56, 1643–1668. [Google Scholar] [CrossRef] [PubMed]
  92. Arifin, S.A.; Falasca, M. Lysophosphatidylinositol signalling and metabolic diseases. Metabolites 2016, 6, 6. [Google Scholar] [CrossRef] [PubMed]
  93. Kita, Y.; Shindou, H.; Shimizu, T. Cytosolic phospholipase A2 and lysophospholipid acyltransferases. Biochim. Biophys. Acta 2019, 1864, 838–845. [Google Scholar] [CrossRef] [PubMed]
  94. Balboa, M.A.; Balsinde, J.; Dillon, D.A.; Carman, G.M.; Dennis, E.A. Proinflammatory macrophage-activating properties of the novel phospholipid diacylglycerol pyrophosphate. J. Biol. Chem. 1999, 274, 522–526. [Google Scholar] [CrossRef] [PubMed]
  95. Chakravarthy, M.V.; Lodhi, I.J.; Yin, L.; Malapaka, R.R.; Xu, H.E.; Turk, J.; Semenkovich, C.F. Identification of a physiologically relevant endogenous ligand for PPARα in liver. Cell 2009, 138, 476–488. [Google Scholar] [CrossRef] [PubMed]
  96. Lee, J.M.; Lee, Y.K.; Mamrosh, J.L.; Busby, S.A.; Griffin, P.R.; Pathak, M.C.; Ortlund, E.A.; Moore, D.D. A nuclear-receptor-dependent phosphatidylcholine pathway with antidiabetic effects. Nature 2011, 474, 506–510. [Google Scholar] [CrossRef] [PubMed]
  97. O’Donnell, V.B.; Murphy, R.C. New families of bioactive oxidized phospholipids generated by immune cells: Identification and signaling actions. Blood 2012, 120, 1985–1992. [Google Scholar] [CrossRef] [PubMed]
  98. Casas, J.; Gijón, M.A.; Vigo, A.G.; Crespo, M.S.; Balsinde, J.; Balboa, M.A. Phosphatidylinositol 4,5-bisphosphate anchors cytosolic group IVA phospholipase A2 to perinuclear membranes and decreases its calcium requirement for translocation in live cells. Mol. Biol. Cell 2006, 17, 155–162. [Google Scholar] [CrossRef] [PubMed]
  99. Koeberle, A.; Shindou, H.; Harayama, T.; Shimizu, T. Palmitoleate is a mitogen, formed upon stimulation with growth factors, and converted to palmitoleoyl-phosphatidylinositol. J. Biol. Chem. 2012, 287, 27244–27254. [Google Scholar] [CrossRef]
  100. Thürmer, M.; Gollowitzer, A.; Pein, H.; Neukirch, K.; Gelmez, E.; Waltl, L.; Wielsch, N.; Winkler, R.; Löser, K.; Grander, J.; et al. PI(18:1/18:1) is a SCD1-derived lipokine that limits stress signaling. Nat. Commun. 2022, 13, 2982. [Google Scholar] [CrossRef]
  101. Lands, W.E.M. Stories about acyl chains. Biochim. Biophys. Acta 2000, 1483, 1–14. [Google Scholar] [CrossRef] [PubMed]
  102. Murphy, R.C.; Folco, G. Lysophospholipid acyltransferases and leukotriene biosynthesis: Intersection of the Lands cycle and the arachidonate PI cycle. J. Lipid Res. 2019, 60, 219–226. [Google Scholar] [CrossRef] [PubMed]
  103. Mouchlis, V.D.; Chen, Y.; McCammon, J.A.; Dennis, E.A. Membrane allostery and unique hydrophobic sites promote enzyme substrate specificity. J. Am. Chem. Soc. 2018, 140, 3285–3291. [Google Scholar] [CrossRef] [PubMed]
  104. Hayashi, D.; Mouchlis, V.; Dennis, E.A. Each phospholipase A2 type exhibits distinct selectivity toward sn-1 ester, alkyl ether, and vinyl ether phospholipids. Biochim. Biophys. Acta 2022, 1867, 159067. [Google Scholar] [CrossRef] [PubMed]
  105. Hayashi, D.; Mouchlis, V.; Dennis, E.A. Omega-3 versus omega-6 fatty acid availability is controlled by hydrophobic site geometries of phospholipase A2s. J. Lipid Res. 2021, 62, 100113. [Google Scholar] [CrossRef] [PubMed]
  106. Murakami, M.; Masuda, S.; Ueda-Semmyo, K.; Yoda, E.; Kuwata, H.; Takanezawa, Y.; Aoki, J.; Arai, H.; Sumimoto, H.; Ishikawa, Y.; et al. Group VIB Ca2+-independent phospholipase A2β promotes cellular membrane hydrolysis and prostaglandin production in a manner distinct from other intracellular phospholipases A2. J. Biol. Chem. 2005, 280, 14028–14041. [Google Scholar] [CrossRef] [PubMed]
  107. Deng, X.; Wang, J.; Jiao, L.; Utaipan, T.; Tuma-Kellner, S.; Schmitz, G.; Liebisch, G.; Stremmel, W.; Chamulitrat, W. iPLA2β deficiency attenuates obesity and hepatic steatosis in ob/ob mice through hepatic fatty-acyl phospholipid remodeling. Biochim. Biophys. Acta 2016, 1861, 449–461. [Google Scholar] [CrossRef] [PubMed]
  108. Jiao, L.; Gan-Schreier, H.; Zhu, X.; Wei, W.; Tuma-Kellner, S.; Liebisch, G.; Stremmel, W.; Chamulitrat, W. Ageing sensitized by iPLA2β deficiency induces liver fibrosis and intestinal atrophy involving suppression of homeostatic genes and alteration of intestinal lipids and bile acids. Biochim Biophys Acta 2017, 1862, 1520–1533. [Google Scholar] [CrossRef]
  109. Otto, A.C.; Gan-Schreier, H.; Zhu, X.; Tuma-Kellner, S.; Staffer, S.; Ganzha, A.; Liebisch, G.; Chamulitrat, W. Group VIA phospholipase A2 deficiency in mice chronically fed with high-fat-diet attenuates hepatic steatosis by correcting a defect of phospholipid remodeling. Biochim Biophys Acta 2019, 1864, 662–676. [Google Scholar] [CrossRef]
  110. Zhu, X.; Gan-Schreier, H.; Otto, A.C.; Cheng, Y.; Staffer, S.; Tuma-Kellner, S.; Ganzha, A.; Liebisch, G.; Chamulitrat, W. iPLA2β deficiency in mice fed with MCD diet does not correct the defect of phospholipid remodeling but attenuates hepatocellular injury via an inhibition of lipid uptake genes. Biochim. Biophys. Acta 2019, 1864, 677–687. [Google Scholar] [CrossRef]
  111. Astudillo, A.M.; Balboa, M.A.; Balsinde, J. Compartmentalized regulation of lipid signaling in oxidative stress and inflammation: Plasmalogens, oxidized lipids and ferroptosis as new paradigms of bioactive lipid research. Prog. Lipid Res. 2023, 89, 101207. [Google Scholar] [CrossRef] [PubMed]
  112. Guijas, C.; Bermúdez, M.A.; Meana, C.; Astudillo, A.M.; Pereira, L.; Fernández-Caballero, L.; Balboa, M.A.; Balsinde, J. Neutral lipids are not a source of arachidonic acid for lipid mediator signaling in human foamy monocytes. Cells 2019, 8, 941. [Google Scholar] [CrossRef] [PubMed]
  113. Chilton, F.H. Potential phospholipid source(s) of arachidonate used for the synthesis of leukotrienes by the human neutrophil. Biochem. J. 1989, 258, 327–333. [Google Scholar] [CrossRef] [PubMed]
  114. Chilton, F.H.; Connell, T.R. 1-Ether-linked phosphoglycerides. Major endogenous sources of arachidonate in the human neutrophil. J. Biol. Chem. 1988, 263, 5260–5265. [Google Scholar] [CrossRef] [PubMed]
  115. Pindado, J.; Balsinde, J.; Balboa, M.A. TLR3-dependent induction of nitric oxide synthase in RAW 264.7 macrophage-like cells via a cytosolic phospholipase A2/cyclooxygenase-2 pathway. J. Immunol. 2007, 179, 4821–4828. [Google Scholar] [CrossRef] [PubMed]
  116. Rouzer, C.A.; Kingsley, P.J.; Wang, H.; Zhang, H.; Morrow, J.D.; Dey, S.K.; Marnett, L.J. Cyclooxygenase-1-dependent prostaglandin synthesis modulates tumor necrosis factor-α secretion in lipopolysaccharide-challenged murine resident peritoneal macrophages. J. Biol. Chem. 2004, 279, 34256–34268. [Google Scholar] [CrossRef]
Biomolecules 14 00707 g001
Figure 1. Phospholipid distribution of POA in human monocytes. (A) Cellular POA content in phospholipids as shown by class. The different phospholipid classes were separated by thin-layer chromatography and their POA content was determined by GC-MS after converting the fatty acid glyceryl esters into fatty acid methyl esters. (B) Profile of POA-containing phospholipid molecular species. The distribution profile of POA between phosphatidylcholine (PC, red bars), phosphatidylethanolamine (PE, green bars), phosphatidylinositol (PI, yellow bars), and phosphatidylserine (PS, pink bars) species was determined by LC-MS. The data are shown as mean values ± standard error (n = 3).
Figure 1. Phospholipid distribution of POA in human monocytes. (A) Cellular POA content in phospholipids as shown by class. The different phospholipid classes were separated by thin-layer chromatography and their POA content was determined by GC-MS after converting the fatty acid glyceryl esters into fatty acid methyl esters. (B) Profile of POA-containing phospholipid molecular species. The distribution profile of POA between phosphatidylcholine (PC, red bars), phosphatidylethanolamine (PE, green bars), phosphatidylinositol (PI, yellow bars), and phosphatidylserine (PS, pink bars) species was determined by LC-MS. The data are shown as mean values ± standard error (n = 3).
Biomolecules 14 00707 g001
Biomolecules 14 00707 g002
Figure 2. Characterization of POA incorporation into macrophage phospholipids. (A) Time-course of incorporation into different phospholipid classes. The cells were incubated with [3H]POA for the indicated periods of time. Lipids were then extracted, and [3H]POA incorporation was measured in PC (red), PE (green), PI (yellow), and PS (pink). (B) The cells were exposed to [3H]POA for 30 min, thoroughly washed to eliminate the unincorporated label, and left in culture for 24 h. Afterward, the [3H]POA content in each phospholipid class was measured. The data are shown as mean values ± standard error (n = 3).
Figure 2. Characterization of POA incorporation into macrophage phospholipids. (A) Time-course of incorporation into different phospholipid classes. The cells were incubated with [3H]POA for the indicated periods of time. Lipids were then extracted, and [3H]POA incorporation was measured in PC (red), PE (green), PI (yellow), and PS (pink). (B) The cells were exposed to [3H]POA for 30 min, thoroughly washed to eliminate the unincorporated label, and left in culture for 24 h. Afterward, the [3H]POA content in each phospholipid class was measured. The data are shown as mean values ± standard error (n = 3).
Biomolecules 14 00707 g002
Biomolecules 14 00707 g003
Figure 3. Effect of monocyte activation on the distribution of POA into the different phospholipid classes. The monocytes were exposed to [3H]POA for 30 min, thoroughly washed to eliminate the unincorporated label, and left in culture in the presence of 1 mg/mL zymosan for the indicated periods of time (A), or 1 µM calcium ionophore A23187 for 3 h (B) (unstimulated cell conditions are shown in solid bars; A23187-treated cell conditions are shown in open bars). Afterward, the [3H]POA content in each phospholipid class was measured. The data are shown as mean values ± standard error (n = 3). * p < 0.05, significantly different from the corresponding species in control unstimulated cells (time zero in (A); solid bars in (B)).
Figure 3. Effect of monocyte activation on the distribution of POA into the different phospholipid classes. The monocytes were exposed to [3H]POA for 30 min, thoroughly washed to eliminate the unincorporated label, and left in culture in the presence of 1 mg/mL zymosan for the indicated periods of time (A), or 1 µM calcium ionophore A23187 for 3 h (B) (unstimulated cell conditions are shown in solid bars; A23187-treated cell conditions are shown in open bars). Afterward, the [3H]POA content in each phospholipid class was measured. The data are shown as mean values ± standard error (n = 3). * p < 0.05, significantly different from the corresponding species in control unstimulated cells (time zero in (A); solid bars in (B)).
Biomolecules 14 00707 g003
Biomolecules 14 00707 g004
Figure 4. Changes in POA-containing species in human monocytes. The levels of major POA-containing PC (A–C), PE (D–F), PI (G,H), and PS (I) molecular species in resting (Control) and stimulated monocytes were determined by LC-MS. The data are shown as mean values ± standard error (n = 3). * p < 0.05, significantly different from the corresponding species in control cells. a.u., arbitrary units.
Figure 4. Changes in POA-containing species in human monocytes. The levels of major POA-containing PC (A–C), PE (D–F), PI (G,H), and PS (I) molecular species in resting (Control) and stimulated monocytes were determined by LC-MS. The data are shown as mean values ± standard error (n = 3). * p < 0.05, significantly different from the corresponding species in control cells. a.u., arbitrary units.
Biomolecules 14 00707 g004
Biomolecules 14 00707 g005
Figure 5. Effect of triacsin C and SKF98625 on the movement of POA between phospholipids in zymosan-stimulated monocytes. The [3H]POA-prelabeled cells were either unstimulated (Ctrl, colored bars) or stimulated by 1 mg/mL zymosan for 3 h (Stim, open bars) in the absence (No inhibitor) or presence of 3 µM triacsin C or 10 µM SKF98625, as indicated. Afterward, 3H-radioactivity levels in PC (A) and PI (B) were measured. The data are shown as mean values ± standard error (n = 3). * p < 0.05, ** p < 0.01, significantly different from control (Ctrl).
Figure 5. Effect of triacsin C and SKF98625 on the movement of POA between phospholipids in zymosan-stimulated monocytes. The [3H]POA-prelabeled cells were either unstimulated (Ctrl, colored bars) or stimulated by 1 mg/mL zymosan for 3 h (Stim, open bars) in the absence (No inhibitor) or presence of 3 µM triacsin C or 10 µM SKF98625, as indicated. Afterward, 3H-radioactivity levels in PC (A) and PI (B) were measured. The data are shown as mean values ± standard error (n = 3). * p < 0.05, ** p < 0.01, significantly different from control (Ctrl).
Biomolecules 14 00707 g005
Biomolecules 14 00707 g006
Figure 6. Effect of phospholipase A2 inhibitors on the movement of POA between phospholipids in zymosan-stimulated monocytes. The [3H]POA-prelabeled cells were either unstimulated (Ctrl, colored bars) or stimulated by 1 mg/mL zymosan for 3 h (Stim, open bars) in the absence (No inhibitor) or presence of the following inhibitors: 1 µM pyrrophenone, 25 µM LY311727, 10 µM FKGK18, or 10 µM BEL, as indicated. Afterward, 3H-radioactivity levels in PC (A) and PI (B) were measured. The data are shown as mean values ± standard error (n = 3). * p < 0.05, ** p < 0.01, significantly different from control (Ctrl).
Figure 6. Effect of phospholipase A2 inhibitors on the movement of POA between phospholipids in zymosan-stimulated monocytes. The [3H]POA-prelabeled cells were either unstimulated (Ctrl, colored bars) or stimulated by 1 mg/mL zymosan for 3 h (Stim, open bars) in the absence (No inhibitor) or presence of the following inhibitors: 1 µM pyrrophenone, 25 µM LY311727, 10 µM FKGK18, or 10 µM BEL, as indicated. Afterward, 3H-radioactivity levels in PC (A) and PI (B) were measured. The data are shown as mean values ± standard error (n = 3). * p < 0.05, ** p < 0.01, significantly different from control (Ctrl).
Biomolecules 14 00707 g006
Biomolecules 14 00707 g007
Figure 7. LysoPI production by zymosan-stimulated human monocytes. Time-course of the zymosan-stimulated formation of LPI(18:0) (A) and LPI(18:1) (B), as measured by LC-MS. These data are shown as mean values ± standard error (n = 3). * p < 0.05, ** p < 0.01, *** p < 0.001 represent significant difference from unstimulated cells at time zero. To assess the effect of phospholipase A2 inhibitors on lysoPI formation, the cells were pretreated for 15 min with 1 µM pyrrophenone (D,G), 1 µM FKGK18 (E,H) or neither (labeled as ‘No inhibitor’) (C,F), as indicated. Afterward, the cells were stimulated with zymosan, and LPI(18:0) (C–E) or LPI(18:1) (F–H) were measured by LC-MS. These data are shown as mean values ± standard error (n = 3). ** p < 0.01, *** p < 0.001, significantly different from control (Ctrl).
Figure 7. LysoPI production by zymosan-stimulated human monocytes. Time-course of the zymosan-stimulated formation of LPI(18:0) (A) and LPI(18:1) (B), as measured by LC-MS. These data are shown as mean values ± standard error (n = 3). * p < 0.05, ** p < 0.01, *** p < 0.001 represent significant difference from unstimulated cells at time zero. To assess the effect of phospholipase A2 inhibitors on lysoPI formation, the cells were pretreated for 15 min with 1 µM pyrrophenone (D,G), 1 µM FKGK18 (E,H) or neither (labeled as ‘No inhibitor’) (C,F), as indicated. Afterward, the cells were stimulated with zymosan, and LPI(18:0) (C–E) or LPI(18:1) (F–H) were measured by LC-MS. These data are shown as mean values ± standard error (n = 3). ** p < 0.01, *** p < 0.001, significantly different from control (Ctrl).
Biomolecules 14 00707 g007
Biomolecules 14 00707 g008
Figure 8. Proposed pathway for the movement of palmitoleic acid from PC to PI in human monocytes. For simplicity, the figure shows the formation of PI(18:0/16:1). Formation of PI(18:1/16:1) would proceed following the same steps when the cPLA2α acts upon PI(18:1/20:4) instead of PI(18:0/20:4).
Figure 8. Proposed pathway for the movement of palmitoleic acid from PC to PI in human monocytes. For simplicity, the figure shows the formation of PI(18:0/16:1). Formation of PI(18:1/16:1) would proceed following the same steps when the cPLA2α acts upon PI(18:1/20:4) instead of PI(18:0/20:4).
Biomolecules 14 00707 g008
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Bermúdez, M.A.; Garrido, A.; Pereira, L.; Garrido, T.; Balboa, M.A.; Balsinde, J. Rapid Movement of Palmitoleic Acid from Phosphatidylcholine to Phosphatidylinositol in Activated Human Monocytes. Biomolecules 2024, 14, 707. https://doi.org/10.3390/biom14060707

AMA Style

Bermúdez MA, Garrido A, Pereira L, Garrido T, Balboa MA, Balsinde J. Rapid Movement of Palmitoleic Acid from Phosphatidylcholine to Phosphatidylinositol in Activated Human Monocytes. Biomolecules. 2024; 14(6):707. https://doi.org/10.3390/biom14060707

Chicago/Turabian Style

Bermúdez, Miguel A., Alvaro Garrido, Laura Pereira, Teresa Garrido, María A. Balboa, and Jesús Balsinde. 2024. "Rapid Movement of Palmitoleic Acid from Phosphatidylcholine to Phosphatidylinositol in Activated Human Monocytes" Biomolecules 14, no. 6: 707. https://doi.org/10.3390/biom14060707

APA Style

Bermúdez, M. A., Garrido, A., Pereira, L., Garrido, T., Balboa, M. A., & Balsinde, J. (2024). Rapid Movement of Palmitoleic Acid from Phosphatidylcholine to Phosphatidylinositol in Activated Human Monocytes. Biomolecules, 14(6), 707. https://doi.org/10.3390/biom14060707

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop